AstraZeneca reaffirms its commitment by partnering with Yayasan Kanker Indonesia (YKI) to educate the public on the importance of early diagnosis.
Details
To commemorate this day, AstraZeneca reaffirms its commitment by partnering with Yayasan Kanker Indonesia (YKI) to educate the public on the importance of early diagnosis. We had the honor of hosting dr. Siti Nadia Tarmizi, M.Epid, Director of Communicable Disease Prevention and Control, Ministry of Health of the Republic of Indonesia, and Prof. Dr. dr. Aru W. Sudoyo, SpPD, KHOM, FINASIM, Chairman of YKI, who shared invaluable insights. Over 50 participants joined us to commemorate this day and learn more about early diagnosis and innovative treatment.
Detecting cancer at an early stage is crucial for improving treatment outcomes and survival rates. Early diagnosis allows patients to access innovative treatments sooner, enhancing their effectiveness and significantly increasing survival chances. AstraZeneca is committed to pushing the boundaries of science to understand cancer and its complexities, discovering, developing, and delivering innovative medicines to eliminate cancer as a cause of death.
We realize that achieving our goals requires a collaborative approach. By engaging with diverse stakeholders across multiple sectors, we can amplify our impact and achieve significantly greater progress than we could independently. Let’s honor those we’ve lost, support those living with cancer, and continue to collaborate to improve outcomes in cancer care.
